ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
July 21, 2025 6:55 AM EDT
TD Cowen analyst Ritu Baral reiterated a Hold rating and $28.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "Lack of proactive disclosure in recent rh74 GTx-related death undermines credibility with investors. Last week, at the start of the International LGMD Conference (Orlando), unsubstantiated media reports disclosed a 51 yr old pt in the Ph1/2 trial of rh74-based GTx SRP-9004 (for LGMD Type 2D) died 11 wks post-Tx... More
July 21, 2025 6:03 AM EDT
BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $20.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "On Friday night, Sarepta (SRPT) reported that the company received an informal request from the Food and Drug Administration (FDA) to voluntarily halt all shipments of Elevidys. The company announced they plan... More
July 18, 2025 2:19 PM EDT
(Updated - July 18, 2025 2:19 PM EDT)
Baird analyst Brian Skorney downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Neutral with a price target of $15.00 (from $25.00).
The analyst comments "Downgrading on broad, existential uncertainty. We feel like it is too little, too late, but... More
